You avoid the wrong FDA regulatory path by classifying the proposed product from its intended use and the means by which it achieves that use, then determining whether multiple regulated constituent parts create a combination product. Only after those questions are settled should you choose a lead FDA center, investigational route, or marketing submission.
An early label based on appearance—“it has hardware, so it’s a device” or “it contains an active ingredient, so it’s a drug”—can push testing, quality planning, labeling, and agency interactions in the wrong direction. You need a written product-jurisdiction analysis that connects claims, mechanisms, configuration, and supporting science. The questions below help you build that analysis in the order FDA applies the governing definitions.
How Do I Know Whether My Product Is a Drug or a Device?
Start with the proposed intended use, indications for use, and the means by which the product is expected to achieve its primary intended purposes. FDA applies the statutory drug and device definitions to the product you plan to market, supported by the scientific information available for that proposed use.
Write the intended use before debating the regulatory category. State the disease, condition, structure, or bodily function involved; the target population; the site and route of use; and the result the product is intended to produce. FDA’s device-determination page separates intended use—the product’s general purpose or function—from indications for use, which describe the disease or condition and intended patient population. Those statements should match your draft labeling, development plan, and commercial claims rather than a narrower description created only to support a preferred pathway.
Then describe the mechanism in testable terms. Identify what contacts the body, what physical or molecular events occur, where those events occur, and which event produces the claimed result. FDA notes that classification analysis focuses on how the product would be expected to achieve its primary intended purposes; full marketing-level proof of effectiveness is not required at the classification stage. A mechanism statement that says only “supports healing,” “improves performance,” or “creates a protective effect” is too vague to distinguish a physical device action from a pharmacological drug action.
Can a Product Still Be a Device If It Has Chemical Action?
Yes. A product can exhibit chemical action and still meet the device definition when that chemical action does not achieve the product’s primary intended purposes within or on the body and the product satisfies the other parts of the device definition.
FDA interprets chemical action as a molecular-level interaction with bodily components that mediates a bodily response, or an interaction with a foreign entity that changes how that entity interacts with the body. The practical test is not whether any chemical reaction occurs. You need to identify whether the claimed medical result depends on that molecular interaction within or on the body. An absorbable suture can be treated as a device when its primary purpose is physically rejoining tissue; its resorption involves chemical action and metabolic activity.
Physical effects can lead to major biological outcomes without turning the product into a drug. FDA describes a topical cyanoacrylate adhesive that polymerizes and forms a film to hold skin edges together, cryogenic wart treatment that works through heat transfer, and an abdominal adhesion barrier that separates tissue physically. Those products do not achieve their stated primary purposes through chemical action within or on the body under FDA’s analysis. Your file should explain the causal chain from product operation to therapeutic effect and cite bench data, scientific literature, material behavior, and other evidence that supports that chain.
What Makes a Product a Combination Product?
A combination product contains constituent parts from different regulated product types: drug and device, biological product and device, drug and biological product, or all three. The legal definition also covers certain separately supplied products that are intended and labeled for use together.
The most familiar form is a single-entity combination product, where constituent parts are physically, chemically, or otherwise combined and produced as one entity. FDA lists drug-eluting stents, transdermal systems, antimicrobial-coated catheters, and prefilled drug-delivery systems among its examples. A prefilled syringe is not treated as a plain device merely because the syringe provides the visible engineering. The drug and delivery device remain constituent parts of the marketed product, and the product-jurisdiction analysis must address the action of each.
Do not confuse “combination product” with any product made from several materials, components, or functions. FDA states that a package containing only devices is not a combination product, and a product containing only drugs is not one either. A device assembled from software, sensors, tubing, and a pump may still be one device product type; two drugs placed in one dosage form do not become a drug-device combination merely because they are combined. The classification of each claimed constituent part must come before the combination-product decision.
Does Packaging or Labeling Products Together Make Them a Combination Product?
It can. FDA’s definition covers co-packaged products containing different regulated product types and certain cross-labeled products supplied separately but intended for use with one another to achieve the intended effect.
Co-packaging is more than placing unrelated merchandise in one shipping carton. FDA lists a drug or vaccine vial packaged with a delivery device, surgical trays containing instruments and drug products, and first-aid kits containing devices and drugs as co-packaged examples. You should identify the product unit offered to the customer, the reason the articles are packaged together, and whether the constituent parts are intended to function together for the medical use. A kit containing only medical devices remains outside the combination-product definition because it lacks different regulated product types.
Cross-labeling can create combination-product status without common packaging. The definition reaches certain separately packaged products when proposed labeling specifies use with an individually identified product, each is required to achieve the intended use or effect, and the applicable labeling conditions are met. FDA gives the pairing of a photosensitizing drug with a specified activating light source as an example. Review instructions for use, compatibility statements, promotional claims, training materials, and development plans together; a product relationship can be established through labeling even when the articles reach the user through separate channels.
How Does Primary Mode of Action Affect the FDA Center and Submission Path?
For a combination product, the primary mode of action is the single mode of action that provides the most important therapeutic action. FDA uses it to assign the lead center with primary jurisdiction for premarket review and regulation.
List every constituent part, its mode of action, and the therapeutic contribution linked to that action. Then explain which action contributes most to the overall intended therapeutic effects and why, using product-specific science rather than component size, cost, novelty, or internal ownership. A device-biological product combination with a biological PMOA is assigned to the FDA component responsible for that biological product; the same assignment logic applies to drug-led and device-led products. When the most important action cannot be determined, FDA’s assignment algorithm considers which center regulates combination products that raise similar safety and effectiveness questions, or which center has the expertise to assess the most consequential questions.
Lead-center assignment guides the usual investigational and marketing route, but it does not erase requirements tied to the other constituent part. FDA states that a drug-PMOA product is typically investigated under an IND and a device-PMOA product under an IDE; marketing authorization is generally associated with the PMOA constituent, including an NDA or ANDA for a drug PMOA and a 510(k), De Novo request, or PMA for a device PMOA. One investigational application is generally sufficient for the combination product, yet it should contain information needed to assess the full product. Some combination products use more than one marketing application, so sponsors should discuss submission structure with the lead reviewing division and the Office of Combination Products when the route is uncertain.
Should I Submit a Pre-RFD or an RFD?
Use a Pre-Request for Designation when you want preliminary, informal, non-binding FDA feedback on classification or center assignment. Use a Request for Designation when you need a formal agency determination.
A Pre-RFD fits an early program when your intended use, design, mechanism evidence, and constituent-part description are developed enough for a meaningful agency assessment but you still need room to refine the proposal. FDA’s current Pre-RFD guidance states that the process can address whether a human medical product is a drug, device, biological product, or combination product and which center would receive it. Informal feedback is valuable for planning, but you should not describe it internally as a binding designation. Major changes to the proposed product can also reduce the value of feedback obtained from an earlier description.
An RFD requires you to recommend a classification or assignment and explain the basis for that recommendation. FDA generally responds in writing within 60 days after the RFD is filed, and the determination applies to the product as described in the designation letter, including its proposed uses or indications. FDA can return an incomplete request, so the submission needs a precise product description, all modes of action, supporting data, comparable products, your recommended outcome, and a reasoned analysis. Contacting the Office of Combination Products before filing can help you identify missing information or poorly framed questions.
What Evidence Helps You Avoid the Wrong Regulatory Path?
Build a classification record that links the proposed claims to the product’s mechanisms, constituent parts, configuration, and PMOA. The strongest file lets another reviewer follow your reasoning without relying on the project team’s preferred business outcome.
Start with a controlled product-jurisdiction memorandum. Include the proposed intended use and indications, product composition and design, diagrams, route and site of use, duration of contact, each mode of action, where each action occurs, and the evidence supporting each statement. Compare your proposal with FDA classification regulations, product databases, public authorization records, and official examples, but don’t treat visual similarity as proof. FDA recommends searching for an existing device classification and similar legally marketed devices, yet it also ties device status to intended use, indications, and the statutory definition.
Add a change trigger to your development controls. FDA states that an RFD determination applies only to the product described and that a new determination may be appropriate when the indication, a component, or information about how the product achieves its primary intended purposes changes. Reassess classification when you revise claims, formulation, coating, dose, software function, delivery method, packaging, cross-labeling, or a constituent part’s therapeutic role. A regulatory path chosen once and never reviewed can become wrong through ordinary product-development decisions, even when the original analysis was sound.
How Do You Classify a Drug, Device, or Combination Product?
- Define the intended use and indications.
- Explain how the product achieves its primary purpose.
- Classify each regulated constituent part.
- Check single-entity, co-packaged, and cross-labeled status.
- Identify the PMOA and seek FDA input when unclear.
Make the Classification Decision Before the Development Plan Hardens
The safest regulatory path begins with a disciplined classification record, not a submission template chosen by habit. Define the claim, trace the mechanism that produces it, classify each constituent part, and test whether the marketed configuration meets the combination-product definition. Use PMOA to support lead-center assignment, then confirm which investigational and marketing submissions fit the full product. Seek a Pre-RFD for preliminary feedback or an RFD for a formal determination when uncertainty can change your development program. Revisit the decision whenever the product, labeling, mechanism evidence, or intended use changes, because classification follows the product you actually propose to market.
References
- U.S. Food and Drug Administration. Classification of Products as Drugs and Devices and Additional Product Classification Issues
- U.S. Food and Drug Administration. How to Determine if Your Product Is a Medical Device
- U.S. Food and Drug Administration. Frequently Asked Questions About Combination Products
- U.S. Food and Drug Administration. Combination Product Definition and Combination Product Types
- U.S. Food and Drug Administration. How to Prepare a Pre-Request for Designation
- U.S. Food and Drug Administration. Office of Combination Products
- Electronic Code of Federal Regulations. 21 CFR Part 3 — Product Jurisdiction